Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq:CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. All of the shares in the offering are being sold by Catalyst.
Related news for (CPRX)
- Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
- Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
- Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
- Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals